Mannitol Fresenius

Mannitol, the active ingredient in Mannitol Fresenius, is an osmotic diuretic presented as an intravenous solution for intravenous use. It lowers intracranial and intraocular pressure, reduces cerebral edema, and promotes renal excretion of water and solutes in patients with renal or neuro‑critical conditions.

GNH USA supplies Mannitol Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to strict quality standards and delivering reliable product availability across multiple regions for critical care applications.

Mannitol is used in clinical situations that require reduction of fluid volume in the brain or promotion of diuresis in renal impairment. - Reduction of intracranial pressure: lowers pressure by creating an osmotic gradient that draws water out of cerebral tissue. - Treatment of cerebral edema: decreases brain swelling, improving neurological function. - Acute renal failure with oliguria: enhances urine output to aid waste elimination. - Promotion of diuresis in various clinical settings: supports fluid removal during surgery or in heart failure management.

Mannitol may be associated with several adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring during infusion. - Nausea: sensation of unease that may lead to vomiting. - Electrolyte imbalance: changes in serum sodium or potassium levels. - Thirst: increased desire for fluids during treatment. - Hypotension: transient drop in blood pressure after rapid administration.

Serious or Rare Side Effects: - Pulmonary edema: accumulation of fluid in the lungs requiring immediate care. - Severe hyponatremia: markedly low sodium that can cause neurological symptoms. - Anaphylactic reaction: rare hypersensitivity with rash, bronchospasm, or shock. - Renal failure worsening: unexpected decline in kidney function. - Cardiac arrhythmia: irregular heart rhythm potentially life‑threatening.

When using Mannitol, clinicians should observe several precautionary measures to minimize risks. - Renal function: assess baseline creatinine and glomerular filtration rate. - Fluid balance: monitor input and output closely to avoid overload. - Electrolytes: check serum sodium and potassium before and during therapy. - Cardiovascular status: observe blood pressure for hypotension or hypertension. - Pregnancy: consider only if potential benefit justifies potential risk to the fetus. - Store at ambient temperature: keep in original container, protect from light and moisture.

Mannitol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Loop diuretics: combined use may cause excessive diuresis and electrolyte loss. - ACE inhibitors: may enhance hypotensive effects and renal impairment. - Vasopressors: can counteract Mannitol‑induced volume shifts, reducing effectiveness.

Moderate Interactions (Monitor Closely): - NSAIDs: may diminish diuretic response and affect renal perfusion. - Antiepileptic drugs: altered serum osmolarity can affect drug levels. - Insulin: rapid fluid shifts may increase risk of hypoglycemia.